Early exclusive access to UK Biobank exome sequences, price paid by each pharmaceutical company in the Regeneron-led consortium, per exome
$10 million
USD per exome, paid by each consortium company, UK
“consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource ... The newly announced collaborators will each commit $10 million to enable a dramatic acceleration of sequencing timelines ... Consortium members will have a limited period of exclusive access to the sequencing data, before the data will be made available to other health researchers by UK Biobank.”
- Kind of source
- The payer's or seller's own page
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- Each of five companies (AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer) paid this for a period of exclusive access to 500,000 exomes linked to health records, while also funding their production; the data later opened to all approved researchers. Regeneron's own contribution was undisclosed.
- Arithmetic
- $10,000,000 per company / 500,000 exomes = $20 per exome for each company (five companies together: $50,000,000 / 500,000 = $100 per exome).